Granules India Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Granules India Limited Pharmaceutical Export Portfolio Dataset — 20 Products, $412.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Granules India Limited — Pharmaceutical Exporter Profile (2026) | 20 Products, $412.3M Trade | TransData Nexus

Granules India Limited

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $412.3M Total Trade · DGFT Verified

Granules India Limited is an Indian pharmaceutical exporter with a total trade value of $412.3M across 20 products in 9 therapeutic categories. Based on 8,357 verified export shipments from Indian Customs (DGFT) records, Granules India Limited is the #1 Indian exporter in 5 products including Metformin, Acetaminophen, Amino. Top exports include Metformin ($113.9M), Acetaminophen ($85.0M), Amino ($85.0M).

Granules India Limited — Export Portfolio & Destination Treemap

Granules India Limited pharmaceutical export portfolio — 20 products across 9 therapeutic categories. Source: Indian Customs (DGFT).

Who is Granules India Limited? — Company Overview & Market Position

Granules India Limited, established in 1984, is a vertically integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. The company specializes in the manufacture and sale of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosage Forms (FDs). Granules India Limited is publicly listed on the National Stock Exchange of India (NSE) under the ticker symbol GRANULES and on the Bombay Stock Exchange (BSE) under the ticker symbol 532482. As of March 2025, the company employed approximately 6,166 individuals.

The company's Corporate Identification Number (CIN) is L24110TG1991PLC012471, and it is registered with the Registrar of Companies in Hyderabad. Granules India Limited's authorized share capital is ₹505,000,000, with a paid-up capital of ₹242,368,716. The company's official website is www.granulesindia.com.

What Does Granules India Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Metformin$113.9M 2

Product Portfolio — Top 20 by Export Value

Granules India Limited exports 20 pharmaceutical products across 9 therapeutic categories. Market leader (#1 exporter) in 5 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Metformin	Diabetes & Endocrine	$113.9M	2,278	24.4%	1
2	Acetaminophen	Analgesics & Antipyretics	$85.0M	1,700	36.6%	1
3	Amino	Nutritional Supplements	$85.0M	1,700	26.3%	1
4	Ibuprofen	Analgesics & Antipyretics	$34.9M	698	6.0%	2
5	Potassium	Nutritional Supplements	$13.8M	276	2.1%	6
6	Paracetamol	Analgesics & Antipyretics	$11.2M	224	3.1%	4
7	Fexofenadine	Antihistamines & Allergy	$9.7M	194	8.8%	1
8	Guaifenesin	Respiratory & OTC	$9.1M	181	33.9%	1
9	Naproxen	Analgesics & Antipyretics	$8.5M	191	6.3%	5
10	Sertraline	CNS & Psychiatric	$7.8M	155	1.4%	7
11	Metoprolol	Cardiovascular	$7.4M	149	0.9%	8
12	Gabapentin	CNS & Psychiatric	$7.0M	140	0.8%	12
13	Cetirizine	Antihistamines & Allergy	$5.7M	116	3.2%	10
14	Loratadine	Antihistamines & Allergy	$4.3M	98	2.5%	4
15	Diphenhydramine	Antihistamines & Allergy	$2.5M	78	7.8%	4
16	Ephedrine	Respiratory & OTC	$1.4M	29	6.4%	4
17	Pseudoephedrine	Respiratory & OTC	$1.4M	29	12.2%	3
18	Azathioprine	Immunosuppressants	$1.4M	39	4.0%	5
19	Tamoxifen	Advanced Oncology	$1.3M	25	8.5%	3
20	Aspirin	Analgesics & Antipyretics	$1.1M	57	2.9%	14

Granules India Limited exports 20 pharmaceutical products across 9 therapeutic categories with a total export value of $412.3M. The company is the #1 Indian exporter in 5 products: Metformin, Acetaminophen, Amino, Fexofenadine, Guaifenesin. The top category is Analgesics & Antipyretics (34.1% of portfolio), followed by Diabetes & Endocrine (27.6%), indicating a concentrated portfolio with the top 5 products accounting for 80.7% of total export value.

Granules India Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Granules India Limited operates 11 manufacturing facilities, including eight in India, two in the United States, and one in Europe. These facilities are approved by leading regulatory agencies, including the US FDA, EDQM, EU GMP, WHO GMP, and others. The company's manufacturing plants are strategically located to serve both domestic and international markets, ensuring a robust supply chain and compliance with global quality standards.

3Key Leadership

The leadership team at Granules India Limited is headed by Managing Director and Chairman Krishna Prasad Chigurupati, who has been with the company since 1994. Other key executives include Mukesh Surana, Chief Financial Officer; PV Srinivas, Chief Technology Officer; Vinodkumar Parur, Chief Human Resources Officer; and Priyanka Chigurupati, Director. The board of directors comprises individuals with diverse expertise, including Arun Sawhney, Lead Independent Director; Saumen Chakraborty, Additional Non-Executive Independent Director; and Sucharita Rao Palepu, Additional Non-Executive Independent Director.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Granules India Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Granules India Limited has a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities are approved by the US FDA, EDQM, EU GMP, WHO GMP, and other regulatory bodies, facilitating market access in these regions. Granules India Limited's product portfolio includes paracetamol, metformin, guaifenesin, and methocarbamol, among others, catering to various therapeutic categories such as antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, and more.

2Emerging Markets

Granules India Limited has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's facilities are approved by WHO GMP, enabling access to these regions. Granules India Limited's product offerings in these markets include a range of pharmaceutical formulations, catering to various therapeutic categories.

3Geographic Strategy

Granules India Limited's geographic strategy involves diversification across multiple regions, including regulated and emerging markets. The company's manufacturing facilities are strategically located to serve both domestic and international markets, ensuring a robust supply chain and compliance with global quality standards. This approach mitigates concentration risk and positions the company for sustainable growth in the global pharmaceutical industry.

Granules India Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Granules India Limited's manufacturing facilities are approved by the US FDA, facilitating market access in the United States. The company's product portfolio includes paracetamol, metformin, guaifenesin, and methocarbamol, among others, catering to various therapeutic categories such as antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, and more.

2WHO & EU GMP

Granules India Limited's manufacturing facilities are approved by WHO GMP and EU GMP, ensuring compliance with international quality standards. The company's product offerings include a range of pharmaceutical formulations, catering to various therapeutic categories.

3CDSCO & Indian Regulatory

Granules India Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers, ensuring compliance with Indian regulatory requirements. The company's facilities are approved by WHO GMP, facilitating export to international markets. Granules India Limited's product portfolio includes paracetamol, metformin, guaifenesin, and methocarbamol, among others, catering to various therapeutic categories such as antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, and more.

Granules India Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Granules India Limited operates in a competitive landscape with several key players in the pharmaceutical industry. The company's product portfolio includes paracetamol, metformin, guaifenesin, and methocarbamol, among others, catering to various therapeutic categories such as antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, and more. Granules India Limited's manufacturing facilities are approved by leading regulatory agencies, including the US FDA, EDQM, EU GMP, WHO GMP, and others, facilitating market access in various regions.

2Key Differentiators

Granules India Limited's key differentiators include its vertically integrated operations, spanning the entire pharmaceutical manufacturing value chain from APIs to FDs. The company's manufacturing facilities are approved by leading regulatory agencies, including the US FDA, EDQM, EU GMP, WHO GMP, and others, facilitating market access in various regions. Granules India Limited's product portfolio includes paracetamol, metformin, guaifenesin, and methocarbamol, among others, catering to various therapeutic categories such as antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, and more.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Granules India Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Granules India Limited has a strong track record in pharmaceutical manufacturing, with a diverse product portfolio and a global presence. The company's manufacturing facilities are approved by leading regulatory agencies, including the US FDA, EDQM, EU GMP, WHO GMP, and others, facilitating market access in various regions. Granules India Limited's product offerings include a range of pharmaceutical formulations, catering to various therapeutic categories such as antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, and more.

2Certifications to Verify

Importers should verify the following certifications when sourcing from Granules India Limited:

FDA Approval: Confirm that the manufacturing facility is registered with the US FDA.

WHO GMP Certification: Ensure that the facility holds a valid WHO GMP certificate.

EU GMP Certification:

Frequently Asked Questions — Granules India Limited

How many pharmaceutical products does Granules India Limited export from India?

Granules India Limited exports 20 pharmaceutical products across 9 therapeutic categories. The top exports are Metformin ($113.9M), Acetaminophen ($85.0M), Amino ($85.0M), Ibuprofen ($34.9M), Potassium ($13.8M). Total export value is $412.3M.

What is Granules India Limited's total pharmaceutical export value?

Granules India Limited's total pharmaceutical export value is $412.3M, based on 8,357 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Granules India Limited the #1 Indian exporter?

Granules India Limited is the #1 Indian exporter in 5 products: Metformin (24.4% market share), Acetaminophen (36.6% market share), Amino (26.3% market share), Fexofenadine (8.8% market share), Guaifenesin (33.9% market share).

What therapeutic categories does Granules India Limited cover?

Granules India Limited exports across 9 therapeutic categories. The largest are Analgesics & Antipyretics (34.1%, 5 products), Diabetes & Endocrine (27.6%, 1 products), Nutritional Supplements (24.0%, 2 products).

Get Full Granules India Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.